Investigating how a specific protein affects Alzheimer's disease
Neurobiological significance of Aqp4 stop codon readthrough
This study is looking at a special protein that helps the brain get rid of harmful substances linked to Alzheimer's disease, and it aims to see if a modified version of this protein can improve brain function for people with Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project ID | NIH-10605249 on NIH RePORTER |
What this research studies
This research focuses on the role of a protein called Aquaporin 4 (Aqp4) in the brain's ability to remove harmful amyloid beta (Aβ) proteins that contribute to Alzheimer's disease. The study aims to understand how a modified version of Aqp4, which can bypass a genetic stop signal, may enhance the clearance of Aβ and potentially improve cognitive function in Alzheimer's patients. Researchers will use advanced techniques to analyze the effectiveness of this modified protein in laboratory models that mimic Alzheimer's disease. By restoring the function of Aqp4, the research hopes to find new ways to combat the cognitive decline associated with Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk for developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve cognitive function and slow the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in enhancing Aβ clearance through similar mechanisms, suggesting potential for success in this approach.
Where this research is happening
Richardson, United States
- University of Texas Dallas — Richardson, United States (Active)
Researchers
- Principal investigator: Sapkota, Darshan — University of Texas Dallas
- Study coordinator: Sapkota, Darshan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.